Enriched HLA-E and CD94/NKG2A interaction limits antitumor CD8+ tumor-infiltrating T lymphocyte responses
Immunotherapy treatments with anti-PD-1 boost recovery in less than 30% of treated cancer patients, indicating the complexity of the tumor microenvironment. Expression of HLA-E is linked to poor clinical outcomes in mice and human patients. However, the contributions to immune evasion of HLA-E, a li...
المؤلفون الرئيسيون: | Abd Hamid, M, Wang, R, Yao, X, Fan, P, Li, X, Chang, X, Feng, Y, Jones, S, Maldonado-Perez, D, Waugh, C, Verrill, C, Simmons, A, Cerundolo, V, McMichael, A, Conlon, C, Wang, X, Peng, Y, Dong, T |
---|---|
التنسيق: | Journal article |
اللغة: | English |
منشور في: |
American Association for Cancer Research
2019
|
مواد مشابهة
-
Enriched HLA-E and CD94/NKG2a interaction limits anti-tumor CD8+ tumor-infiltrating T lymphocyte responses
حسب: Abd Hamid, M, وآخرون
منشور في: (2019) -
HLA-E is expressed on trophoblast and interacts with CD94/NKG2 receptors on decidual NK cells.
حسب: King, A, وآخرون
منشور في: (2000) -
HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C.
حسب: Braud, V, وآخرون
منشور في: (1998) -
Regulation of NK cell functions through interaction of the CD94/NKG2 receptors with the nonclassical class I molecule HLA-E.
حسب: Braud, V, وآخرون
منشور في: (1999) -
HLA class I signal peptide polymorphism determines the level of CD94/NKG2–HLA-E-mediated regulation of effector cell responses
حسب: Lin, Z, وآخرون
منشور في: (2023)